Axsome Therapeutics Inc(AXSM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.76 | Insider Own | 15.65% | Shs Outstand | 52.3M | Perf Week | -7.54% |
| Market Cap | 7.55B | Forward P/E | 36.89 | EPS next Y | 233.08% | Insider Trans | -2.57% | Shs Float | 44.2M | Perf Month | -26.16% |
| Enterprise Value | 7.45B | PEG | - | EPS next Q | -0.63 | Inst Own | 73.28% | Short Float | 7.48% | Perf Quarter | -38.49% |
| Income | -0.19B | P/S | 9.72 | EPS this Y | 20.27% | Inst Trans | 0.22% | Short Ratio | 4.48 | Perf Half Y | -23.13% |
| Sales | 0.78B | P/B | 90.44 | EPS next 5Y | - | ROA | -27.35% | Short Interest | 3.31M | Perf YTD | -21.12% |
| Book/sh | 1.59 | P/C | 23.59 | EPS past 3/5Y | 7.17% -5.89% | ROE | -245.1% | 52W High | -44.63% ($260.19) | Perf Year | 11.2% |
| Cash/sh | 6.11 | P/FCF | - | Sales past 3/5Y | 133.68% - | ROIC | -82.65% | 52W Low | 16.65% ($123.50) | Perf 3Y | 124.92% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 25.87% | Gross Margin | 91.96% | Volatility(W/M) | 4.03% 3.9% | Perf 5Y | 262.96% |
| Dividend TTM | - | EV/Sales | 9.59 | Sales Y/Y TTM | 56.87% | Oper. Margin | -23.55% | ATR (14) | 6.98 | Perf 10Y | 1987.83% |
| Dividend Ex-Date | - | Quick Ratio | 1.34 | EPS Q/Q | -2.09% | Profit Margin | -24.68% | RSI (14) | 21.1 | Recom | 1.13 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.43 | Sales Q/Q | 45.54% | SMA20 | -13.09% ($165.76) | Beta | 0.84 | Target Price | $279.38 |
| Payout | - | Debt/Eq | 2.7 | Earnings | 2026/11/2 | SMA50 | -24.36% ($190.45) | Rel Volume | 1.2 | Prev Close | $145.04 |
| Employees | 925 | LT Debt/Eq | 1.78 | EPS/Sales Surpr. | -10.97% -2.15% | SMA200 | -27.95% ($199.94) | Avg Volume(3M) | 0.74M | Price | $144.06 |
| IPO | 2015/11/19 | Option/Short | Yes/Yes | Trades | 12806 | Volume | 886,185 | Change | -0.68% |
A U.S. biopharmaceutical company specializing in the development and commercialization of treatments for central nervous system (CNS) disorders, including depression, sleep disorders, and migraines. As a CNS-focused drugmaker, it has advanced to the commercialization stage through its own launched products, positioning it as a growth-oriented biotech.
Over the past 1 year, on the lower side
45% below its 1-year high.
Traded about as much as usual. That is 120% of its average volume.
Next earnings report: November 2
6 days to go.
AXSM has weak earning power
Of every $100 in sales, $23.55 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +20.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $972. Peers typically go for $1,575.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +263.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 73.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #36 of 594 in the industry
Based on market cap of $8B.
IBRX#34 ImmunityBio Inc $8B PER - 
ABVX#35 Abivax ADR $8B PER - AXSM#36 Axsome Therapeutics Inc $8B PER - 
PRAX#37 Praxis Precision Medicines Inc $7B PER - 
IONS#38 Ionis Pharmaceuticals Inc $7B PER - 
FAQ
What kind of company is AXSM?
AXSM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AXSM?
The market cap of AXSM is approximately $7.5B, ranking 1,071 within its sector.
What is the 52-week high and low for AXSM?
AXSM has recorded a 52-week high of $260.19 and a low of $123.50.
